Biospecimen Core

生物样本核心

• 批准号: 10333518
• 负责人: Olca Basturk
• 金额: $ 12.35万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-20 至 2027-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10333518
• 关键词: Adjuvant; American; Basic Science; Biological Assay; Biological Specimen Banks; Blood; CLIA certified; Cancer Patient; Cell Line; Cell Survival; Clinical; Collaborations; Collection; Consent; Databases; Diagnosis; Documentation; Effectiveness; Enrollment; Ensure; Evaluation; Excision; Formalin; Freezing; Generations; Genomics; Goals; Heterogeneity; Human; Immunohistochemistry; Infrastructure; Laboratories; Malignant Neoplasms; Malignant neoplasm of pancreas; Measures; Memorial Sloan-Kettering Cancer Center; Microdissection; Microscopic; Molecular Analysis; Morphology; Mutation; Neoadjuvant Therapy; Normal tissue morphology; Organoids; Pancreas; Pancreatic Ductal Adenocarcinoma; Paraffin Embedding; Pathologic; Pathologist; Pathology; Patient-Focused Outcomes; Patients; Plasma; Play; Protocols documentation; Quality Control; Randomized Controlled Trials; Recording of previous events; Reproducibility; Research; Research Personnel; Research Project Grants; Resistance; Resources; Role; Sampling; Services; Specimen; Standardization; System; Techniques; Therapeutic Human Experimentation; Tissue Microarray; Tissue Sample; Tissues; Translational Research; Treatment Protocols; Tumor Tissue; Work; adjudicate; anticancer research; biobank; cancer cell; college; cost effective; data quality; design; diagnostic value; exome sequencing; follow-up; human tissue; laser capture microdissection; molecular diagnostics; molecular oncology; mouse model; pancreatic ductal adenocarcinoma model; pancreatic neoplasm; peripheral blood; programs; prospective; quality assurance; relational database; response; single cell sequencing; treatment response; tumor

PROJECT SUMMARY – BIOSPECIMEN CORE The Biospecimen Core is designed to provide expert support to the translational research efforts of the Memorial Sloan Kettering Cancer Center (MSK) Pancreas SPORE. The Core will leverage and extend the very active tissue banking program and molecular diagnostics capabilities of the MSK Precision Pathology Biobanking Core (PPBC), which anchors 4 other MSK SPOREs and the MSK Center for Pancreatic Cancer Research. The SPORE Biospecimen Core will play an essential role in collection, annotation, storage, distribution, and tracking of pancreatic cancer biospecimens (tissue and blood) from patients enrolled in institutional biospecimen banking protocols and therapeutic research protocols. Detailed biospecimen annotation, including documentation of preanalytic processing variables, pathology findings, and patient clinical history information will be recorded in robust relational databases. We will conduct rigorous data quality assurance and quality control measures, and standardized longitudinal follow-up of all consented patients with materials in the pancreatic cancer biospecimen repository. The Core will also provide SPORE investigators with expert histopathological evaluation of tumor samples, as well as assistance in performing and interpreting immunohistochemical assays, selecting tissue for microdissection for downstream analysis, constructing tissue microarrays, and facilitating patient-derived organoid creation. The specific aims of the core are to (1) maintain and expand the collection, annotation, and storage of biospecimens for pancreatic cancer research, (2) perform systematic pathologic evaluation of all relevant ductal pancreatic adenocarcinoma samples and to prepare appropriate biospecimens for use by SPORE investigators, and (3) provide systematic microscopic assessment of response to therapy. Given the significant heterogeneity of pancreatic cancers, each of these aims requires expertise beyond what existing resources can provide, underscoring the need for this Core. All of the research projects will rely extensively on the Biospecimen Core to achieve their translational research objectives.

项目总结-生物样本核心 生物样本核心旨在为生物技术领域的转化研究工作提供专家支持。 纪念斯隆凯特琳癌症中心（MSK）胰腺孢子。核心将利用和扩展 MSK Precision Pathology的活跃组织库计划和分子诊断功能 生物库核心（PPBC），它锚定4个其他MSK SPORE和MSK胰腺癌中心 Research.孢子生物标本核心将在收集，注释，储存， 来自入组研究的患者的胰腺癌生物标本（组织和血液）的分布和跟踪 机构生物标本库方案和治疗研究方案。详细生物标本 注释，包括分析前处理变量、病理学发现和患者临床 历史信息将被记录在可靠的关系数据库中。我们将严格数据质量 保证和质量控制措施，以及对所有同意的患者进行标准化纵向随访， 胰腺癌生物标本库中的材料。核心还将提供SPORE调查人员 肿瘤样本的专家组织病理学评估，以及协助执行和解释 免疫组织化学测定，选择用于显微切割的组织用于下游分析，构建组织 微阵列，并促进患者来源的类器官产生。核心的具体目标是：（1）保持 并扩大胰腺癌研究生物标本的收集、注释和储存，（2）执行 对所有相关导管胰腺癌样本进行系统病理学评价， 适当的生物标本供SPORE研究者使用，以及（3）提供系统的显微镜检查 评估对治疗的反应。考虑到胰腺癌的显著异质性， 实现这些目标需要现有资源无法提供的专门知识，这突出表明需要这一核心。所有 的研究项目将广泛依赖于生物标本核心，以实现其转化研究 目标.